Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
about
The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancerIdentification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent
P2860
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
@ast
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
@en
type
label
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
@ast
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
@en
prefLabel
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
@ast
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
@en
P2093
P2860
P356
P1476
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
@en
P2093
Brian K Law
Mary E Law
Patrick E Corsino
Satya Narayan
P2860
P304
P356
10.1124/MOL.115.099325
P577
2015-05-27T00:00:00Z